Monoclonal antibodies

Antibodies
#Antibody #Antibody-based therapeutics #eBook #Monoclonal antibodies #Stability characterisation

New eBook: Efficiently develop antibody-based therapeutics 

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing.  Antibodies are affected by many factors along their journey to become therapeutics. Read More

#News

Antibodies
#Afucosylated mAb expression #Antibody #Antibody-dependent cellular cytotoxicity #Glycoengineered antibodies #Monoclonal antibodies

New App Note: Afucosylated mAb expression and antibody efficacy

Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in… Read More

#News

#Cell line development #Drug discovery #Lab analytics #Monoclonal antibodies #Pharmacokinetics / Pharmacodynamics

Analysis in the lab: Advancing drug discovery

Learn about the critical role analytical tools and equipment have in helping to advance drug discovery research in this DDW eBook sponsored by Sartorius. This eBook covers: Opinions on the major trends in lab analytics. Measuring the pharmacokinetics of monoclonal antibodies. Best practices in cell line development Access the… Read More

#DDW eBooks #Intelligence

Antibody
#Drug discovery #Monoclonal antibodies #Webinar

Webinar: Octet BLI for antibody discovery

Join DDW & Charles River Laboratories in this free webinar examining how the company uses Octet Bio-Layer Interferometry (BLI) to help inform its drug discovery campaigns and workflows. In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet Bio-Layer Interferometry (BLI) into… Read More

#News

Child with eczema
#Atopic dermatitis #Biologics #Dermatology #Eczema #Monoclonal antibodies

First biologic therapy for young children with severe eczema

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal… Read More

#News

#Antibody #Drug discovery #Monoclonal antibodies #Webinar

Webinar – applications in early monoclonal antibody discovery

In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. The webinar elaborates on the use of the Octet BLI for quality control of proteins,… Read More

#News

#Drug discovery #High Throughput #Monoclonal antibodies #Webinar

Webinar: Applications in early monoclonal antibody discovery

Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to… Read More

#News

#Antibody reagents #Drug discovery #Monoclonal antibodies #Webinar

High throughput Octet BLI applications in early monoclonal antibody discovery

Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to… Read More

Webinar date:
Brought to you by Sartorius
#Webinars

#Monoclonal antibodies #Regulatory

Follow a monoclonal antibody through IND and BLA filings

In this infographic by NanoTemper, follow the steps a monoclonal antibody takes on its journey when filing for both an investigational new drug (IND) and biologics license application (BLA). In the infographic, learn about: • The typical timeline and steps for the… Read More

#News

#AstraZeneca #Clinical trials #Monoclonal antibodies

First patients dosed in trial for AstraZeneca’s Lupus treatment  

The first patients have been dosed in a Phase III clinical trial testing AstraZeneca’s treatment for lupus nephritis (LN).   The IRIS Phase III trial will be conducted in multiple countries across two years and is expected to enrol up to 360 participants aged between 18 and 70. Read More

#News

#Covid-19 #Monoclonal antibodies #Reagents #Research

Sino Biological launches panel of research reagents for Omicron variant

Sino Biological has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus. The new Omicron product line includes recombinant Omicron spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognising the Omicron spike protein, and the Omicron pseudovirus assay CRO service. These… Read More

#News

#Biologics #Drug development #Drug discovery #Immuno-oncology #Monoclonal antibodies

The potential of small molecules and biologics for new therapeutics 

Listen to this article on the DDW Podcast: Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. He talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.  Since its formation in 2011, Tonix Pharmaceuticals has harnessed the power of clinical… Read More

#Business & Investment #Exclusive Content #News

#Antibodies #Collaboration #Drug development #Drug discovery #Monoclonal antibodies

Nautilus and Abcam partner to accelerate proteome exploration  

Nautilus Biotechnology and Abcam have announced a strategic development and supply partnership to leverage Abcam’s recombinant monoclonal antibody development technologies and expertise to enhance Nautilus’ reagent research and development.   The partnership will initially focus on the collaborative development of affinity binding reagents for use on the… Read More

#News #Trending News

#Antibodies #Covid-19 #Drug discovery #Drug therapy #Infographic #Monoclonal antibodies #Research

Study illuminates surfaces of spike most resistant to antibody escape 

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, which was generated by a global collaboration comparing nearly all leading clinical candidates. The new research, published in Science, will guide the development of more effective Covid-19 antibody… Read More

#Covid-19 #News